Previous close | 28.53 |
Open | 28.47 |
Bid | 28.40 x 3200 |
Ask | 28.41 x 1300 |
Day's range | 28.40 - 28.67 |
52-week range | 25.20 - 40.37 |
Volume | |
Avg. volume | 42,527,788 |
Market cap | 161.075B |
Beta (5Y monthly) | 0.58 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.05 |
Earnings date | 30 Jul 2024 - 05 Aug 2024 |
Forward dividend & yield | 1.68 (5.89%) |
Ex-dividend date | 09 May 2024 |
1y target est | 31.48 |
A Delaware federal jury has determined that AstraZeneca Plc (NASDAQ:AZN) must pay Pfizer Inc (NYSE:PFE) $107.5 million in damages, concluding that AstraZeneca’s blockbuster lung cancer drug, Tagrisso, infringed on Pfizer’s Wyeth unit’s patent rights. The jury found that AstraZeneca’s Tagrisso violated two patents held by Pfizer, which cover methods for treating cancer using the breast cancer drug Nerlynx. Also Read: Double Good News For AstraZeneca’s Breast Cancer Drugs. Puma Biotechnology Inc (
After disappointing sales for their Covid vaccines last year, drugmakers are hoping for an August rollout of the updated shot.
This new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.